

# WAVE – growing, developing, progressing

53 members (48 women + 5 men)

Region balance - 23 countries from all EACS regions

Europe East 11

Europe North 13

Europe South 12

Europe West 13

RoW 4

11 members of the Scientific Committee

2 chairs

Newsletter opening – above 60%

Surveys response – above 40%


Organised in thematic sub-groups





#### WAVE in Ukraine – since 2019

Simultaneous translation (Ukrainian, Russian, English)



#### Development 2021-2022 and beyond:

- 1.ongoing education (online seminar every 2 months) and one onsite meeting per year
- 2. CME credits, targeted content, responsiveness

Leads: Karoline Aebi-Popp (Switzerland), Justyna D. Kowalska (Poland)

Involved: Marta Vasylyev (Ukraine), Sergii Antoniak (Ukraine), Chas Zhytia Plus (NGO, Ukraine)

## WAVE's Collaboration with External Conferences



The annual conference in Egypt bringing together clinicians, scientists and associates from the entire country, presenting the latest research

Yvonne Gilleece

Maria Jesus
Perez Elias


HIV Glasgow
Joint Session

October 2020

Menopause and Gender Disparity outcomes in women living with HIV:

- Key questions in WLWHIV and ageing: menopause, frailty, and cancer screening
- 90:90:90. Are the Differences Between Women and Men Changing?


November 2020 – February 2021




- How to **measure stigma** in potential PrEP providers, and anticipated/internalised stigma in potential beneficiaries
- How to measure quality of life/mental health ("The fourth 90") in people needing PrEP and people taking it?
- How to make PrEP more accessible (de-medicalization?)?
- How to identify women who might benefit from PrEP?



## **WAVE's Collaboration with External Research Groups**




Evaluation of current HIV PMTCT recommendations in participating cohorts with regard to AZT prophylaxis and breastfeeding (17 countries – EPPICC and WAVE).



First randomised controlled trial on safety and efficacity of DAAs after the first tremester in pregnant women with HCV The trial includes women with co-infections (both HIV and HepB).

## **Combination prevention - since 2019**




## **Development 2021-2022 and beyond:**

1. Identifying gaps in access and missed opportunities for testing/offering PrEP by Launching survey among women on PrEP Launching survey among PrEP providers

2. Drafting recommendations for the Guidelines Panel

Leads: Yvonne Gilleece (UK), Ben Collins (UK) for questionnaire; Maria Jesus Perez (Spain) for National Cohorts Review Involved: Karoline Aebi-Popp (Switzerland), NAM, Sophia Forum, AVAC



### **Development 2021-2022 and beyond:**

1.Identifying good practices across Europe to improve management of co-morbidities in WLWH in menopausal age

2. Creating network for the future studies at European level in the frame of topics resulting from the literature review (in negotiation with journals specialising in HIV

Respiratory diseases in WLWH

→ Ageing (Focus on quality of life)


Sexual and reproductive health in ageing WLWH

Leads: Umbelina Caixas (Portugal), Teresa Branco (Portugal)

Involved: Shema Tariq (UK), Panagiota Lourids (Greece), Anna Hachfeld (Switzerland), Gordana Dragovic Lukic (Serbia), Nneka Nwokolo (UK), Deniz Goekengin (Turkey)



## Migrant women – since 2021



What are the reasons for late HIV diagnosis in migrant women in Europe ?

To what extent is perception of low risk is the main factor?

#### Development 2021-202 and beyond:

- 1.designing and launching survey among NGOs and official institutions to identify gaps (results to be published)
- 2.survey among migrant women (results to be published)
- 3.creating a tool for designing culturally appropriated information kits

Lead: Nina Weis (Denmark)

Involved: Dagny Krankowska (Poland), Panagiota Lourida (Greece), Melvina Woode-Owusu (United Kingdom)



## **WAVE input to Guidelines Panel in 2021**

